Northland analyst Carl Byrnes initiated coverage of TriSalus Life Sciences (TLSI) with an Outperform rating and $12.50 price target
Northland analyst Carl Byrnes initiated coverage of TriSalus Life Sciences (TLSI) with an Outperform rating and $12.50 price target